+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Acadia Pharmaceuticals Inc  - logo

Acadia Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease, Phase II trial for the treatment of schizophrenia and Phase II study for the treatment of Alzheimer's disease. The company was founded in 1993 and is headquartered in San Diego, California.

Rett Syndrome - Pipeline Insight, 2020 - Product Thumbnail Image

Rett Syndrome - Pipeline Insight, 2020

  • Drug Pipelines
  • February 2020
  • 106 Pages
From
From
Antipsychotic Drugs: Technologies and Global Markets - Product Thumbnail Image

Antipsychotic Drugs: Technologies and Global Markets

  • Report
  • September 2018
  • 174 Pages
From
From
Dementia - Pipeline Review, H1 2020 - Product Thumbnail Image

Dementia - Pipeline Review, H1 2020

  • Drug Pipelines
  • February 2020
  • 469 Pages
From
Global Parkinson's Disease Drugs Market Outlook 2022 - Product Thumbnail Image

Global Parkinson's Disease Drugs Market Outlook 2022

  • Report
  • January 2018
  • 100 Pages
From
From
From
From
Alzheimer s: Epidemiology Overview and Insights - Product Thumbnail Image

Alzheimer s: Epidemiology Overview and Insights

  • Report
  • April 2018
  • 50 Pages
From
From
From
From
Drug Overview: Nuplazid - Product Thumbnail Image

Drug Overview: Nuplazid

  • Report
  • March 2018
  • 16 Pages
From
Rhinitis: Epidemiology Overview and Insights - Product Thumbnail Image

Rhinitis: Epidemiology Overview and Insights

  • Report
  • April 2018
  • 50 Pages
From
Rhinitis: Market Intelligence Review and Insights - Product Thumbnail Image

Rhinitis: Market Intelligence Review and Insights

  • Report
  • April 2018
  • 50 Pages
From
From
Schizophrenia - Pipeline Review, H1 2020 - Product Thumbnail Image

Schizophrenia - Pipeline Review, H1 2020

  • Drug Pipelines
  • May 2020
  • 383 Pages
From
Loading Indicator
adroll